13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
83 檔
9.9%
During the Q4 2024 filing period, Affinity Asset Advisors, LLC (CIK: 0001773195) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.2B across 83 reported positions.
During Q4 2024, Affinity Asset Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.05% | — | — | |
| 2 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.10% | -0.68% | +1.50% | |
| 3 | APGE | Apogee Therapeutics Inc | Stock-Other | 5.66% | +0.33% | +40.28% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 4.37% | -2.15% | EXIT | |
| 5 | ALKS | Alkermes plc | Stock-Healthcare | 4.24% | +0.79% | +10.00% | |
| 6 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.14% | -1.61% | -41.67% | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.11% | — | +1.54% | |
| 8 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.41% | -0.52% | -17.50% | |
| 9 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.15% | -0.01% | +15.00% | |
| 10 | NUVL | Nuvalent Inc-a | Stock-Other | 2.99% | -0.05% | -15.56% | |
| 11 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.57% | +1.80% | +65.39% | |
| 12 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.49% | -0.52% | EXIT | |
| 13 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.46% | -2.87% | EXIT | |
| 14 | VERA | Vera Therapeutics Inc | Stock-Other | 2.41% | -0.04% | -2.30% | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.37% | +0.29% | +9.26% | |
| 16 | MESO | Mesoblast Ltd- Spon Adr | Stock-Other | 2.23% | — | — | |
| 17 | ✓ | Merus N V | Stock-Other | 2.19% | — | +140.66% | |
| 18 | CHRS 1.5 04-15-26Bond | Coherus Oncology Inc | Bond | 2.17% | — | — | |
| 19 | OMER 5.25 02-15-26Bond | Omeros CORP | Bond | 1.96% | — | -27.87% | |
| 20 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.73% | +0.28% | -3.79% | |
| 21 | ARVN | Arvinas Inc | Stock-Other | 1.62% | — | +180.00% | |
| 22 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.59% | — | +24.49% | |
| 23 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.47% | — | +40.75% | |
| 24 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.46% | -0.03% | -10.03% | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.42% | — | — | |
| 26 | GERN | Geron CORP | Stock-Other | 1.07% | — | +50.00% | |
| 27 | AMGN | Amgen Inc | Stock-Healthcare | 1.05% | — | — | |
| 28 | RZLT | Rezolute Inc | Stock-Other | 1.03% | — | -7.35% | |
| 29 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 1.00% | +0.26% | — | |
| 30 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.96% | +1.27% | +5.39% | |
| 31 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.85% | — | -6.25% | |
| 32 | ERAS | Erasca Inc | Stock-Other | 0.84% | -0.12% | — | |
| 33 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.78% | — | +420.80% | |
| 34 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.77% | — | +20.00% | |
| 35 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.76% | -0.10% | -7.69% | |
| 36 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.74% | -0.58% | EXIT | |
| 37 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.67% | +0.08% | NEW | |
| 38 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.67% | +0.01% | — | |
| 39 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.58% | -0.14% | — | |
| 40 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.56% | -0.03% | +160.00% | |
| 41 | FLNA | Filana Therapeutics Inc | Stock-Other | 0.55% | — | +20.02% | |
| 42 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.55% | +1.39% | +1123.92% | |
| 43 | ✓ | Stock-Other | 0.48% | — | — | ||
| 44 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.47% | +0.31% | — | |
| 45 | INSM | Insmed Inc | Stock-Healthcare | 0.46% | -0.92% | — | |
| 46 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.45% | -0.01% | +11.72% | |
| 47 | CMPS | Compass Pathways PLC | Stock-Other | 0.43% | -0.13% | +183.02% | |
| 48 | GALT | Galectin Therapeutics Inc | Stock-Other | 0.43% | — | +105.71% | |
| 49 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.43% | +0.15% | — | |
| 50 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.41% | -0.04% | -69.60% |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 83 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, XENE, APGE) accounted for 9.9% of total reported equity market value during Q4 2024.
During Q4 2024, Affinity Asset Advisors, LLC's top holdings by market value included XBI (9.1%)、XENE (6.1%)、APGE (5.7%). The largest single position, XBI, represented 9.1% of total portfolio value.
In Q4 2024, Affinity Asset Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.